# PRESS RELEASE 2023

## Ferring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive licensing agreement

Ferring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive…

## New data show durable response following treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)

…

## Ferring Named in Fortune’s 2023 Change the World List

## Royalty Pharma and Ferring Pharmaceuticals enter into US $500 million royalty agreement for new intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg)

## Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors

Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals appoints new…

## Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023

Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the…

## Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in…

## Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle® (follitropin delta) at the congress of the Pacific Society for Reproductive Medicine

Ferring announces abstract of the first prospective, multi-national, real-world study of Rekovelle®…

## Approval of new medicines in 2022 sets Ferring on course for future growth and diversification

Approval of new medicines in 2022 sets Ferring on course for future…

## Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer

Ferring Pharmaceuticals appoints Pierre-Yves Berclaz as Executive Vice President, Chief Medical Officer…